Abstract
We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.
| Original language | English |
|---|---|
| Pages (from-to) | 227-233 |
| Number of pages | 7 |
| Journal | Chemotherapy |
| Volume | 42 |
| Issue number | SUPPL. 3 |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Basic and clinical studies on FK037 in respiratory infection. / Fukuhara, H.; Inadome, J.; Kakazu, T.; Nakamura, H.; Kaneshima, H.; Saito, A.; Kusano, Nobuchika; Nakasone, I.; Furugen, Y.; Taira, S.; Hokama, S.; Tateyama, M.; Irabu, Y.; Ueji, H.
In: Chemotherapy, Vol. 42, No. SUPPL. 3, 1994, p. 227-233.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Basic and clinical studies on FK037 in respiratory infection
AU - Fukuhara, H.
AU - Inadome, J.
AU - Kakazu, T.
AU - Nakamura, H.
AU - Kaneshima, H.
AU - Saito, A.
AU - Kusano, Nobuchika
AU - Nakasone, I.
AU - Furugen, Y.
AU - Taira, S.
AU - Hokama, S.
AU - Tateyama, M.
AU - Irabu, Y.
AU - Ueji, H.
PY - 1994
Y1 - 1994
N2 - We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.
AB - We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.
UR - http://www.scopus.com/inward/record.url?scp=0028127043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028127043&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0028127043
VL - 42
SP - 227
EP - 233
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
IS - SUPPL. 3
ER -